BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21159206)

  • 1. All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein.
    Hoang TC; Bui TK; Taguchi T; Watanabe T; Sato Y
    J Exp Clin Cancer Res; 2010 Dec; 29(1):165. PubMed ID: 21159206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
    Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling.
    Ikezoe T; Yang Y; Nishioka C; Bandobashi K; Nakatani H; Taguchi T; Koeffler HP; Taguchi H
    Cancer Sci; 2006 Sep; 97(9):945-51. PubMed ID: 16916320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
    Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W
    Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
    Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.
    He W; Xu L; Ding J; Song L; Yang W; Klooster I; Pilco-Janeta DF; Serrano C; Fang H; Jiang G; Wang X; Yu J; Ou WB
    Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166690. PubMed ID: 36921738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
    Falkenhorst J; Grunewald S; Mühlenberg T; Marino-Enriquez A; Reis AC; Corless C; Heinrich M; Treckmann J; Podleska LE; Schuler M; Fletcher JA; Bauer S
    Oncotarget; 2016 Jul; 7(27):41390-41403. PubMed ID: 27167336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.
    Bauer S; Parry JA; Mühlenberg T; Brown MF; Seneviratne D; Chatterjee P; Chin A; Rubin BP; Kuan SF; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2010 Jan; 70(1):150-9. PubMed ID: 20028860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
    Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
    Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
    Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
    Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
    Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
    Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
    Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
    Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
    Kinsella P; Greene LM; Bright SA; Pollock JK; Butini S; Campiani G; Bauer S; Williams DC; Zisterer DM
    Invest New Drugs; 2016 Apr; 34(2):159-67. PubMed ID: 26885657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.